Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost

Frauke Muecksch1, Zijun Wang24, Alice Cho1,4, Christian Gaebler2, Tarek Ben Tanfous2, Justin DaSilva1, Eva Bednarski1, Victor Ramos5, Shuai Zong7, Brianna Johnson2, Raphael Raspe6, Dennis Schaefer-Babajew1, Irina Shimeliovich7, Mridushi Daga2, Kai-Hui Yao8, Fabian Schmidt1, Katrina G. Millard2, Martina Turroja2, Mila Jankovic2, Thiago Y. Oliveira1, Anna Gazuymay6, Marina Caskey2, Theodora Hatzioannou2, Paul D. Bieniasz1,3 & Michel C. Nussenzweig2,3

The Omicron variant of SARS-CoV-2 infected many vaccinated and convalescent individuals1–3. Despite the reduced protection from infection, individuals who received three doses of an mRNA vaccine were highly protected from more serious consequences of infection4. Here we examine the memory B cell repertoire in a longitudinal cohort of individuals receiving three mRNA vaccine doses5,6. We find that the third dose is accompanied by an increase in, and evolution of, receptor-binding domain (RBD)-specific memory B cells. The increase is due to expansion of memory B cell clones that were present after the second dose as well as the emergence of new clones. The antibodies encoded by these cells showed significantly increased potency and breadth when compared with antibodies obtained after the second dose. Notably, the increase in potency was especially evident among newly developing clones of memory cells, which differed from persisting clones in targeting more conserved regions of the RBD. Overall, more than 50% of the analysed neutralizing antibodies in the memory compartment after the third mRNA vaccine dose neutralized the Omicron variant. Thus, individuals receiving three doses of an mRNA vaccine have a diverse memory B cell repertoire that can respond rapidly and produce antibodies capable of clearing even diversified variants such as Omicron. These data help to explain why a third dose of a vaccine that was not specifically designed to protect against variants is effective against variant-induced serious disease.

We studied the immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination in a longitudinal cohort of 42 volunteers with no prior history of SARS-CoV-2 infection1,5 who were recruited between 21 January 2021 and 14 December 2021 for sequential blood donation. The volunteers received either the Moderna (mRNA-1273; n = 8) or Pfizer-BioNTech (BNT162b2; n = 34) mRNA vaccine. Volunteers ranged in age from 23 to 78 years old; 48% were male and 52% were female (Methods and Supplementary Table 1). Samples were obtained at the following time points: 2.5 weeks after the prime, 1.3 and 5 months after the second vaccine dose and 1 month after the third dose.

Plasma binding and neutralization

Plasma IgM, IgG and IgA responses to SARS-CoV-2 Wuhan-Hu-1 receptor-binding domain (RBD) were measured by enzyme-linked immunosorbent assay (ELISA)5,6. While a significant decrease was observed in antibody reactivity at 5 months after the second vaccine dose, anti-RBD IgG titres were significantly increased after a third dose of an mRNA vaccine (P < 0.0001) (Fig. 1a and Supplementary Table 1). The resulting titres were similar to those observed 1.3 months after the second dose (P > 0.99) (Fig. 1a). IgM and IgA titres were lower than IgG titres, and, although IgM titres were unchanged during the observation period, IgA titres were also significantly increased after the third vaccine dose (Extended Data Fig. 1 and Supplementary Table 1).

The plasma neutralizing activity in 42 participants was measured using HIV-1 pseudotyped with Wuhan-Hu-1 SARS-CoV-2 spike protein5,6 (Fig. 1b and Supplementary Table 1). While a 7.3-fold decrease in neutralizing titres occurred between 1.3 and 5 months after the second vaccine dose, administration of a third vaccine dose boosted neutralizing titres 11.9-fold, resulting in a geometric mean half-maximal neutralizing titre (NT50) of 3,244 against Wuhan-Hu-1 (Fig. 1b). Plasma neutralizing antibodies elicited by mRNA vaccination are more potent against Wuhan-Hu-1 than variants5,6. Consistent with prior reports5,7–10, the third vaccine dose significantly boosted geometric mean NT50 values by 16-fold, 12-fold and 37-fold for the Beta, Delta and Omicron BA.1 variants, respectively. The level of activity against the Beta and Delta variants was not significantly different from that against Wuhan-Hu-1.
Fig. 1 | Plasma ELISAs and neutralizing activity. a, Graph showing area under the curve (AUC) for plasma IgG antibody binding to SARS-CoV-2 Wuhan-Hu-1 RBD after prime, 1.3 months and 5 months after the second vaccination (Vax)29 and 1 month after the third vaccination booster (Vax)3 for n = 42 samples. Lines connect longitudinal samples. m, month. b, Graph showing anti-SARS-CoV-2NTe values of plasma measured by a SARS-CoV-2 pseudotype virus neutralization assay in 293T-ACE2 cells using wild-type (WT) Wuhan-Hu-132 SARS-CoV-2 pseudovirus32,33 in the plasma samples shown in a. c, Plasma neutralizing activity against the indicated SARS-CoV-2 variants of interest or concern for n = 15 randomly selected samples assayed in HT1080Ace2c1.14 cells. Wuhan-Hu-1 and Omicron BA.1 NTe values were derived from ref. 7. Pseudoviruses in c were based on a spike protein that also included the R63G substitution, which disrupts the furin cleavage site and increases particle infectivity. All experiments were performed at least in duplicate. Red bars and values in a–c represent geometric mean values. Statistical significance in a and b was determined by two-tailed Kruskal–Wallis test with subsequent Dunn’s multiple-comparisons test. Statistical significance in c was determined by two-tailed Friedman test with subsequent Dunn’s multiple-comparisons test. P-values are as indicated.

whereas the activity against Omicron BA.1 was 16-fold lower than that against Wuhan-Hu-1 (P = 0.58, P = 0.24 and P = 0.0013, respectively) (Fig. 1c). The correlates of protective neutralizing titers against Omicron BA.1 are not defined. Nevertheless, given the correlation between neutralizing antibody levels and protection from Wuhan-Hu-1 infection4–6, the reduced activity against Omicron BA.1 in recipients of a third dose of vaccine probably explains why vaccinated individuals remained particularly susceptible to infection by this variant.

Memory B cells

Under physiological conditions, memory B cells produce little if any secreted antibody. However, when challenged with antigen as in a breakthrough infection, these cells undergo clonal expansion and produce antibody-secreting plasma cells and memory and germinal centre B cells48. To examine the effects of the third vaccine dose on the memory compartment in our longitudinal cohort, we performed flow cytometry experiments using phycoerythrin (PE)- and Alexa-Fluor-647 (AF647)-labelled Wuhan-Hu-1 RBDs (Fig. 2a and Extended Data Fig. 2). Individuals who received a third vaccine dose developed significantly increased numbers of Wuhan-Hu-1 RBD-binding memory cells compared with those who received only two doses or who were naturally infected6–11 (Fig. 2a, b). The number of memory cells produced after the third dose was not significantly higher than for vaccinated convalescent individuals (P > 0.08) (Fig. 2b). An increased proportion of memory B cells circulating after the third dose expressed IgG and lower levels of CD71 (Extended Data Fig. 2c).

We obtained 1,370 paired antibody sequences from five individuals who were sampled 5 months after the second vaccine dose and 1 month after the third vaccine dose. Two and three of these participants were additionally sampled 2.5 weeks after the first dose and 1.3 months after the second dose, respectively6–8 (Fig. 2c and Supplementary Table 2). After the third vaccine dose, all individuals examined showed expanded clones of memory B cells that were either persisting clones of memory B cells of the same clonal family detected at two or more time points after the initial vaccination or unique clones of memory B cells detected at only a single time point (Fig. 2c). Clones observed uniquely after the third vaccine dose could represent entirely new lineages elicited by the boost or memory cells that were present below the limit of detection at earlier time points. As at earlier time points, the IGHV3-30, IGHV3-53 and IGHV4-31 genes were over-represented 1 month after the third dose6–11 (Extended Data Fig. 3). Thus, there is a persistent bias in IGHV gene representation in memory that is common to most individuals.

Expanded clones of memory cells accounted for 33% and 47% of the repertoire 5 months after the second dose and 1 month after the third dose, respectively (Fig. 2c and Extended Data Fig. 4a). The relative increase in clonality was due in part to an average 3.1-fold expansion of persisting Wuhan-Hu-1 RBD-specific memory B cells (P < 0.0001) (Fig. 2d). Consistent with the relatively modest number of additional cell divisions by persisting clones, these clones accumulated on average only two additional somatic mutations, suggesting a germline-centre-independent process8 (Fig. 2e and Extended Data Fig. 4b).

In comparison with the increase observed in the number of newly emerging unique clones of memory cells at 5 months after the second dose, the increase in these clones after the third dose was more modest (1.7-fold) and did not reach statistical significance (P = 0.086) (Fig. 2d). Antibodies from these cells were more mutated than those from the unique clones present 5 months after the second vaccine dose, as were antibodies that were represented only once (singlets). In both cases, the numbers of somatic mutations were significantly greater than those observed 5 months after the second dose, indicating persisting evolution and cell division (P < 0.0009 and P < 0.0001, respectively) (Fig. 2e and Extended Data Fig. 4). Therefore, a third mRNA vaccine dose is associated with expansion and further evolution of the memory B cell compartment.

Monoclonal antibodies

We cloned the sequences for and expressed 472 monoclonal antibodies, including 1 representative monoclonal antibody from each clonally expanded family and at least 9 randomly selected monoclonal antibodies from individual memory B cells detected only once in each participant (Supplementary Table 3). When tested by ELISA, 459 of these antibodies bound to Wuhan-Hu-1 RBD, indicating the high efficiency of the RBD-specific memory B cell isolation method used here (Extended Data Fig. 5 and Supplementary Table 3). Moreover, 191 antibodies obtained after the third vaccine dose were compared with 34 antibodies isolated after the prime as well as with 79 and 168 antibodies isolated 1.3 and 5 months after the second vaccine dose, respectively. Overall, there was no significant change in binding over time or with the number of vaccine doses (Extended Data Fig. 5a and Supplementary Table 3). This was true for all antibodies combined as
Fig. 2 | Anti-SARS-CoV-2 RBD memory B cells after a third vaccination.
a. Representative flow cytometry plots showing dual binding of AF647- and PE-labelled RBD from Wuhan-Hu-1 by single sorted B cells from five individuals 5 months after the second vaccine dose and 1 month after the third vaccine dose (additional gating strategy given in Extended Data Fig. 2). The percentage of Wuhan-Hu-1 RBD-specific B cells is indicated. b. Graph summarizing the number of Wuhan-Hu-1 RBD-specific memory B cells per 10 million B cells for the individual denoted above the circle. The number inside the circle indicates the number of clonal Wuhan-Hu-1 RBD-specific memory B cells per 10 million B cells isolated from five participants. Each dot represents one clone illustrated in c (n = 331). The left panel (black dots) represents persisting clones, and the right panel (grey dots) represents time point-unique clones. c. Pie charts showing the distribution of IgG antibody sequences observed for memory B cells from five individuals after the prime, 1.3 and 5 months after the second vaccine dose and 1 month after the third vaccine dose. Time points are indicated to the left of the charts. The number inside the circle indicates the number of sequences analysed for the individual denoted above the circle. The pie slice size is proportional to the number of clonally related sequences. The black outline and associated numbers indicate the percentage of clonal sequences detected at each time point. Coloured slices indicate expanded persisting clones found at multiple time points within the same individual, grey slices indicate expanded clones unique to the time point and white slices indicate sequences isolated only once per time point. d. Graph showing the number of clonal Wuhan-Hu-1 RBD-specific memory B cells per 10 million B cells isolated from five participants. Each dot represents one clone illustrated in c (n = 331). The left panel (black dots) represents persisting clones, and the right panel (grey dots) represents time point-unique clones. e. Number of nucleotide somatic hypermutations (SHM) in IGHV and IGKV in all sequences detected 5 months after the second vaccine dose (n = 512) or 1 month after the third vaccine dose (n = 554) compared with the somatic hypermutations in IGHV and IGKV in all sequences detected approximately 9 months (median, 266 days; range, 265–273 days) after infection with or without later vaccination (grey dots). Red bars and numbers represent geometric mean values (b, d) or median values (e). Statistical difference was determined by two-tailed Kruskal–Wallis test with subsequent Dunn’s multiple-comparisons test (b, d) or by two-tailed Mann–Whitney test (e). P values are as indicated.
(P = 0.69)\(^{15,17}\) (Fig. 3a). The improved neutralizing activity was most evidenced among unique clones, with a marked change in IC\(_{50}\) from 323 ng ml\(^{-1}\) 1.3 months after the second vaccine dose to 67 ng ml\(^{-1}\) at 1 month after the third dose (P = 0.034) (Fig. 3b and Supplementary Table 3). Persisting clones also showed improved neutralizing activity after the third dose (P = 0.043); although a trend towards improved neutralizing activity was evident among single antibodies, the difference did not reach statistical significance (Fig. 3b, Extended Data Fig. 5d and Supplementary Tables 3 and 4). In all cases, the relative potency of the antibodies isolated 1 month after the third dose was similar to that of antibodies isolated from convalescent vaccinated individuals 12 months after infection (Fig. 3a, b). Taken together, these results indicate significant improvement in the neutralizing potency against Wuhan-Hu-1 of the antibodies expressed in the memory B cell compartment 1 month after administration of a third mRNA vaccine dose compared with that observed 1.3 months after the second dose. Newly detected singlets and unique clones of expanded memory B cells detected only after the third vaccine dose accounted for most of the improvement in neutralizing activity between 5 months after the second dose and 1 month after the third dose.

**Epitopes and neutralization breadth**

The majority of the anti-RBD neutralizing antibodies obtained from vaccinated individuals after the second vaccine dose belong to class 1 and class 1, which target a region overlapping the ACE2-binding site\(^{13,19}\) (Fig. 4a). These antibodies are generally more potent than class 3 and class 4 antibodies, which target the more conserved base of the RBD and do not directly interfere with ACE2 binding\(^{27}\) (Fig. 4a and Extended Data Fig. 6). Whereas class 1 and class 2 antibodies that develop early are susceptible to mutations in and around the ACE2-binding site found in many of the variants of concern, evolved versions of the same antibodies can be resistant\(^{5,30}\). According to structural information and sequence conservation among betacoronaviruses, antibodies that
span class 3 or class 4 and either class 1 or class 2 are potentially broader than those spanning class 1 or class 2 alone because their epitopes include conserved sequences, and they might be more potent than antibodies from class 3 or class 4 alone because they could interfere directly with the interaction between ACE2 and the RBD (Fig. 4b and Extended Data Fig. 6).

To examine the epitopes targeted by RBD-binding antibodies after the third vaccine dose, we performed biolayer interferometry (BLI) experiments in which a preformed antibody–RBD (HuBu-Hu) complex was exposed to a second antibody targeting one of the four classes of structurally defined epitopes (C105 for class 1, C144 for class 2, C135 for class 3 and C118 for class 4; refs 16,19) (Fig. 4a). Among these random RBD-binding antibodies tested, 20, 29 and 36 exhibited neutralizing activity with an IC_{50} of lower than 1,000 ng ml^{-1} from 1.3 and 5 months after the second vaccine dose and 1 month after the third dose, respectively. As might be expected, the largest group of RBD-binding antibodies obtained after the second vaccine dose belonged to class 1/2 (Fig. 4c). Although the overall distribution of classes for antibodies binding RBD did not change significantly between 1.3 and 5 months after the second dose, the relative representation of class 1 and class 2 binding RBD did not change significantly between 1.3 and 5 months after the second vaccine dose and n = 36 monoclonal antibodies isolated 1 month after the third vaccine dose. Red bars and numbers indicate geometric mean values. Statistical significance was determined using the two-tailed Mann–Whitney test. P values are as indicated. d, Ring plots showing the fraction of neutralizing (IC_{50} < 1,000 ng ml^{-1}) and non-neutralizing (IC_{50} > 1,000 ng ml^{-1}) antibodies (represented by light grey and dark grey, respectively) for the indicated SARS-CoV-2 pseudoviruses. The numbers in the inner circles correspond to the numbers of antibodies tested.
antibodies, with an initial dominance of antibodies in class 1/2 followed by increasing representation of class 1/4 and class 3 over time (Fig. 4e).

The neutralizing breadth of the antibodies elicited by infection increases significantly after 6 months11,17,20, whereas no statistically significant increase in breadth has been observed 5 months after the second dose of an mRNA vaccine6. To determine whether neutralizing antibodies in clones that persisted from 5 months after the second dose to 1 month after the third dose developed increased breadth, we compared 18 antibody pairs that were randomly selected across participants and had measurable neutralizing activity against Wuhan-Hu-1. Neutralizing activity was measured against a panel of SARS-CoV-2 pseudoviruses harbouring RBD amino acid substitutions representative of variants, including Delta and Omicron BA.1 (Fig. 5a and Supplementary Table 5). The clones were passed by antibodies belonging to classes 1/2, 2/3 and 3, as determined by BLI (Fig. 5a). Of the 18 antibody pairs, 15 neutralized pseudovirus carrying the Delta RBD amino acid substitutions at low antibody concentrations at both time points, with IC50 values of ~1–154 ng ml−1 (Fig. 5a and Supplementary Table 5). Although the Omicron BA.1 pseudovirus showed the highest degree of neutralization resistance, 11 of the 18 antibodies isolated 1 month after the third dose neutralized this virus, 9 at an IC50 of below 120 ng ml−1 (Fig. 5a and Supplementary Table 5). Most pairs of antibodies obtained from clones persisting between 5 months after the second vaccine dose and 1 month after the third dose showed exceptionally broad neutralization, and there was little change in antibody breadth within the analysed pairs (Fig. 5a).

We extended the analysis to compare the activity of antibodies present in memory cells at 1.3 months after the second dose to that of antibodies detected uniquely 1 month after the third vaccine dose. A representative group of antibodies was selected across participants and was tested against viruses pseudotyped with spike proteins containing the RBD of Wuhan-Hu-1, Delta and Omicron BA.1 (Fig. 5b and Supplementary Table 6). We found that the proportion of Omicron BA.1-neutralizing antibodies increased from 15% after the second dose to 50% among the unique antibodies found after the third dose (P = 0.035, Fisher’s exact test; Fig. 5b). This increase in frequency of Omicron-neutralizing antibodies is consistent with the observation that a third vaccine dose increased the frequency of Omicron RBD-binding B cells compared with samples collected shortly before the boost21. Among all antibodies evaluated, the increase in breadth between the second and third vaccine doses was reflected by an increase in potency from 689 to 124 ng ml−1 for the IC50 against Omicron BA.1 (P = 0.0004; Fig. 5c and Supplementary Tables 5 and 6). Similar results were observed for Delta neutralization (Fig. 5c). Thus, memory B cells clones emerging after the third vaccine dose showed increasing breadth and potency against pseudoviruses representing variants that were not present in the vaccine.

Finally, we compared the neutralization breadth of antibodies elicited by the third vaccine dose, measured approximately 9 months after the prime, with that of antibodies obtained from a cohort of convalescent unvaccinated individuals 12 months after infection. The latter showed a significant increase in neutralizing breadth over time after infection17–19 (Fig. 5d). The two groups of antibodies were equally and remarkably broad. Moreover, 92% and 94% of the convalescent and third-dose antibodies neutralized pseudoviruses carrying the Beta RBD, and 27% and 56% neutralized Omicron BA.1, respectively. Thus, the antibodies elicited by the third dose of vaccine were at least as broad as those elicited by infection (Fig. 5d).

**Discussion**

Memory B cells can develop from the germinal centre or directly from a germinal centre-independent activated B cell compartment14. B cells residing in germinal centres undergo multiple rounds of division, mutation and selection, whereas those in the activated compartment undergo only a limited number of divisions and carry fewer mutations41. Both pathways remain active throughout the immune response22,23. Our data indicate that the third dose of mRNA vaccines against SARS-CoV-2 expands persisting clones of memory B cells and a cohort of previously undetected clones that carry mutations indicative of germinal centre residence. The latter differ from persistent clones in that they appear to target more conserved regions of the RBD. Several different mechanisms could account for the antigenic shift, including epitope masking by high-affinity antibodies elicited by earlier vaccine doses that primarily target the less conserved RBD24,25,26,27.

Passively administered antibodies are protective against SARS-CoV-2 infection and can prevent serious disease if provided early24–28. The third dose of mRNA vaccines boosts plasma antibody responses to multiple SARS-CoV-2 variants, including Omicron, although the levels are insufficient to prevent breakthrough infection in many individuals2,3. The third dose also elicits increased numbers of memory B cells that express more potent and broader antibodies18,23. Although our data do not exclude the possibility that Omicron-specific memory was present before and was unaffected by the boost, others have demonstrated that the boost increases the frequency of Omicron RBD-binding memory B cells27. Our antibody cloning data provide a mechanistic explanation for the observed increase in Omicron-specific memory B cells after the boost. Although the memory B cells expressing more potent and broader antibodies do not appear to contribute to circulating plasma antibody levels, upon challenge with antigen in the form of a vaccine or infection, they produce large amounts of antibodies within 3–5 days30. Passive administration of antibodies within this same time window prevents the most serious consequences of infection25,28,31. Thus, rapid recall by memory T cells and a diversified and expanded memory B cell compartment are likely to be key mechanisms that contribute to the enhanced protection against severe disease by a third mRNA vaccine dose.

**Online content**

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41586-022-04778-y.

1. Chaguza, C. et al. Rapid emergence of SARS-CoV-2 Omicron variant is associated with infection advantage over Delta in vaccinated persons. Med. https://doi.org/10.1101/2022.01.22.22269660 (2022).
2. Kuhlmann, C. et al. Breakthrough infections with SARS-CoV-2 Omicron despite mRNA vaccine booster dose. Lancet 399, 625–626 (2022)
3. Nemet, I. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N. Engl. J. Med. 386, 492–494 (2022).
4. Danza, P. et al. SARS-CoV-2 infection and hospitalization among adults aged ≥ 18 years, by vaccination status, before and during SARS-CoV-2 B.1.1.529 (Omicron) variant predominance—Los Angeles County, California, November 7, 2021–January 8, 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 177–181 (2022).
5. Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 816–822 (2021).
6. Cho, A. et al. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature 600, 517–522 (2022).
7. Schmidt, F. et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. N. Engl. J. Med. 386, 599–601 (2022).
8. Gruell, H. et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat. Med. 28, 477–480 (2022).
9. Pajon, R. et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N. Engl. J. Med. 386, 1088–1091 (2022).
10. Wang, K. et al. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2 Preprint at medRxivhttps://doi.org/10.1101/2021.09.02.21261735 (2021).
11. Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 3, e52–e61 (2022).
12. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).
13. Gilbert, P. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43–50 (2022).
14. Victoria, G. D. & Nussenzweig, M. C. Germinal centers. Annu. Rev. Immunol. 40, 413–442 (2022).
15. Wang, Z. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature* **595**, 426–431 (2021).
16. Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* **584**, 437–442 (2020).
17. Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**, 639–644 (2021).
18. Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. *Nature* **588**, 682–687 (2020).
19. Yuan, M. et al. Structural basis of a shared antibody response to SARS-CoV-2. *Science* **369**, 1119–1123 (2020).
20. Muecksch, F. et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. *Immunity* **54**, 1853–1868 (2021).
21. Goel, R. R. et al. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. *Cell* https://doi.org/10.1016/j.cell.2022.04.009 (2022).
22. Viant, C. et al. Antibody affinity shapes the choice between memory and germinal center B cell fates. *Cell* **183**, 1298–1311 (2020).
23. Viant, C. et al. Germinal center-dependent and -independent memory B cells produced throughout the immune response. *J. Exp. Med.* **218**, e20202489 (2021).
24. Zhang, Y. et al. Germinal center B cells govern their own fate via antibody feedback. *J. Exp. Med.* **210**, 457–464 (2013).
25. Gupta, A. et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. *N. Engl. J. Med.* **385**, 1941–1950 (2021).
26. Taylor, P. C. et al. Neutralizing monoclonal antibodies for treatment of COVID-19. *Nat. Rev. Immunol.* **21**, 382–393 (2021).
27. Li, D., Sempowski, G. D., Saunders, K. O., Acharya, P. & Haynes, B. F. SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment. *Annu. Rev. Med.* **73**, 1–16 (2022).
28. Wrammert, J. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. *N. Engl. J. Med.* **384**, 238–251 (2021).
29. O’Brien, M. P., Hou, P. & Weinreich, D. M. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. Reply. *N. Engl. J. Med.* **385**, e70 (2021).
30. Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. *Nature* **453**, 667–671 (2008).
31. Gottlieb, R. L. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. *J. Am. Med. Assoc.* **325**, 632–644 (2021).
32. Wu, F. et al. A new coronavirus associated with human respiratory disease in China. *Nature* **579**, 265–269 (2020).
33. Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. *J. Exp. Med.* **217**, e20201181 (2020).
Methods

Study participants
Participants were healthy volunteers who had previously received the initial two-dose regimen of either the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) mRNA vaccine against the WT (Wuhan-Hu-1) strain of SARS-CoV-2. For this study, participants were recruited for serial blood donations at The Rockefeller University Hospital in New York between 21 January and 14 December 2021. No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. The majority of participants (n = 32) were follow-ups from a longitudinal cohort that we previously reported on, while a smaller subgroup of individuals (n = 10) was de novo recruited for this study (for details, see Supplementary Table 1). Eligible participants (n = 42) were healthy adults with no history of infection with SARS-CoV-2 during or before the observation period (as defined by clinical history and confirmed through serology testing) who had received two doses of one of the two currently approved SARS-CoV-2 mRNA vaccines, Moderna (mRNA-1273) and Pfizer-BioNTech (BNT162b2). Additionally, a subgroup of individuals (n = 34) who had received a third vaccine dose was included. The specifics of each participant’s vaccination regimen were at the discretion of the individual and their healthcare provider, consistent with current dosing and interval guidelines, and, as such, not influenced by participation in our study. Exclusion criteria included incomplete vaccination status (defined as fewer than two doses), the presence of clinical signs and symptoms suggestive of acute infection with SARS-CoV-2, or positive reverse transcription PCR (RT–PCR) results for SARS-CoV-2 in saliva or positive COVID-19 serology. No other parameters that could lead to potential self-selection bias were used to exclude or include patients. After enrolment, participant plasma samples obtained after the third vaccine dose were tested for binding activity toward the nucleocapsid (N) protein (Sino Biological, 40588-V08B) of SARS-CoV-2. The absence of serological activity towards N protein was used to ensure a negative history for infection with SARS-CoV-2 for each participant. Participants presented to The Rockefeller University Hospital for blood sample collection and were asked to provide details of their vaccination regimen, possible side effects, comorbidities and possible COVID-19 history. Clinical data collection and management were conducted using the software IRIS by iMedIRIS (version 11.02). All participants provided written informed consent before participation in the study, and the study was conducted in accordance with Good Clinical Practice. The study was performed in compliance with all relevant ethical regulations, and the protocol (DRO-1006) for studies with human participants was approved by the Institutional Review Board of The Rockefeller University. For detailed participant characteristics, see Supplementary Table 1.

Blood sample processing and storage
Peripheral blood mononuclear cells (PBMCs) obtained from samples collected at The Rockefeller University were purified as previously reported by gradient centrifugation and were stored in liquid nitrogen or at −20 °C or lower temperatures. Before experiments, aliquots of plasma samples were considered to indicate non-binders.

ELISAs
ELISAs 34, 35 used to evaluate antibody binding to SARS-CoV-2 Wuhan-Hu-1 RBD were performed by coating high-binding 96-half-well plates (Corning, 3690) with 50 μl per well of a 1 μg ml−1 protein solution in PBS overnight at 4 °C. The plates were washed six times with washing buffer (1× PBS with 0.05% Tween-20 (Sigma-Aldrich)) and were incubated with 170 μl per well blocking buffer (1× PBS with 2% BSA and 0.05% Tween-20 (Sigma)) for 1 h at room temperature. Immediately after blocking, monoclonal antibodies or plasma samples were added to PBS and were incubated for 1 h at room temperature. Plasma samples were assayed at a 1:66 starting dilution with 10 additional threefold serial dilutions. Monoclonal antibodies were tested at a starting concentration of 10 μg ml−1 with 10 additional fourfold serial dilutions. Plates were washed six times with washing buffer and were then incubated with anti-human IgG, IgM or IgA secondary antibody conjugated to horseradish peroxidase (HRP) (Jackson ImmunoResearch, 109-036-088 and 109-035-129 and Sigma, A0295) in blocking buffer at a 1:5,000 dilution (IgM and IgG) or 1:3,000 dilution (IgA). Plates were developed by addition of the HRP substrate 3,3′,5,5′-tetramethylbenzidine (TMB) (ThermoFisher) for 10 min (plasma samples) or 4 min (monoclonal antibodies). The developing reaction was stopped by adding 50 μl of 1 M H2SO4, and absorbance was measured at 450 nm with an ELISA microplate reader (FluosStar Omega, BMG Labtech) with Omega and Omega MARS software for analysis. For plasma samples, a positive control (plasma from participant COV72, diluted 66.6-fold with 10 additional 3-fold serial dilutions in PBS) was added to every assay plate for normalization. The average of its signal was used for normalization of all other values on the same plate with Excel software before calculating the area under the curve using Prism version 9.3 (GraphPad). Negative controls of pre-pandemic plasma samples from healthy donors were used for validation; details of this process have previously been reported 16. For monoclonal antibodies, the ELISA half-maximal effective concentration (EC50) was determined using four-parameter nonlinear regression (GraphPad Prism version 9.3). EC50 values above 1,000 ng ml−1 were considered to indicate non-binders.

Proteins
The mammalian expression vector encoding the RBD of SARS-CoV-2 (GenBank, MN985325.1; spike protein residues 319–539) has previously been described 36.

SARS-CoV-2-pseudotyped reporter virus
A panel of plasmids expressing RBD-mutant SARS-CoV-2 spike proteins in the context of pSARS-CoV-2-S Δγ 19 (Wuhan-Hu-1) has previously been described 36,37,38. Variant pseudoviruses resembling SARS-CoV-2 variants Delta (B.1.617.2) and Omicron BA.1 (B.1.1.529.1), as described previously, were generated by introduction of substitutions using synthetic gene fragments (IDT) or overlap extension PCR-mediated mutagenesis and Gibson assembly. In particular, the following variant-specific deletions and substitutions were introduced:

Beta: D80A, D156–158, L452R, T478K, D614G, P681R, D950N
Omicron BA.1: A67V, Δ69–70, T95I, G142D, Δ143–145, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K477N, N440K, G446S, S477N, T478K, E484A, Q493K, Q499K, Q577K, N501Y, Y505H, T547K, N501Y, N502K, H675Y, H679K, P681H, N764K, D796Y, N856K, Q954H, N969K, N969K, L981F

The EC484K, K417N, E484K/N501Y, and L452R/T478K substitutions, as well as the deletions/substitutions corresponding to the variants of concern listed above, were incorporated into a spike protein that also included the R683G substitution, which disrupts the furin cleavage site and increases particle infectivity. The neutralizing activity against mutant pseudoviruses was compared with that against a WT SARS-CoV-2 spike sequence (NC_045512), carrying R683G where appropriate.

SARS-CoV-2-pseudotyped particles were generated as previously described 36,37,38. In brief, 293T (CRl-11268) cells obtained from ATCC were transfected with pNL4-3ΔEnv-NanoLuc and pSARS-CoV-2-S Δγ 19. Particles were collected 48 h after transfection, filtered and stored at −80 °C.
All cell lines used in this study were checked for mycoplasma contamination by Hoechst staining and confirmed negative.

**Pseudotyped virus neutralization assay**

Fourfold serially diluted plasma samples (from healthy donors or individuals who received mRNA vaccines) or monoclonal antibodies were incubated with SARS-CoV-2-pseudotyped virus for 1 h at 37 °C. The mixture was subsequently incubated with 293Tux cells (for all WT neutralization assays) or HT1080Ace2cl14 cells (for all mutant panels and variant neutralization assays) for 48 h, after which the cells were washed with PBS and lysed with Laemmli Cell Culture lysis 5× reagent (Promega). Nanoluc luciferase activity in lysates was measured using the Nano-Glo Luciferase Assay System (Promega) with the Glomax Navigator (Promega). The relative luminescence units were normalized to those derived from cells infected with SARS-CoV-2-pseudotyped virus in the absence of plasma or monoclonal antibodies. The NT50 values for plasma or the IC50 and 90% inhibitory concentration (IC90) values for monoclonal antibodies were determined using four-parameter nonlinear regression (least-squares regression method without weighting; constraints: top = 1, bottom = 0) (GraphPad Prism).

**Biotinylation of viral protein for use in flow cytometry**

Purified and Avi-tagged SARS-CoV-2 Wuhan-Hu-1 RBD was biotinylated using the BirA biotin–protein ligase kit according to the manufacturer’s instructions (Avidity) as described previously. Ovalbumin (Sigma, A5503-1G) was biotinylated using the EZ-Link instructions. Single CD3−CD8−CD14−CD16−CD20+Ova−RBD−PE+RBD (Ova) for 30 min on ice. AccuCheck Counting Beads (Life Technologies, NIR (BioLegend, 423105) and fluorophore-labelled RBD and ovalbumin anti-CD14-APC-eFluor 780 (Invitrogen, 47-0149-42) as well as Zombie 47-0086-42), anti-CD16-APC-eFluor 780 (Invitrogen, 47-0168-41) and 780 (Invitrogen, 47-0037-41), anti-CD8-APC-eFluor 780 (Invitrogen, 47-0168-41) were incubated in fluorescence-activated cell sorting (FACS) buffer (1× PBS, 2% FCS, 1 mM EDTA) with the above antibodies, B cells were also stained with the following anti-human antibodies (all at a 1:200 dilution): anti-CD20-PeCy7 (BD Biosciences, 563262) or to streptavidin-BB515 for a phenotyping panel (BD Biosciences, 564453). RBD was conjugated to streptavidin–PE (BD Biosciences, 554061) and streptavidin–BV711 for single-cell sorts (BD Biosciences, 563262) or to streptavidin–AF647 (BioLegend, 405237).

**Flow cytometry and single-cell sorting**

Single-cell sorting by flow cytometry has previously been described. In brief, PBMCs were enriched for B cells by negative selection using a pan-B cell isolation kit according to the manufacturer’s instructions (Miltenyi Biotec, 130-101-638). The enriched B cells were incubated in fluorescence-activated cell sorting (FACS) buffer (1× PBS, 2% FCS, 1 mM EDTA) with the above antibodies, B cells were also stained with the following anti-human antibodies (all at a 1:200 dilution): anti-CD20-PeCy7 (BD Biosciences, 535793), anti-CD3-APC-eFluor 780 (Invitrogen, 47-0037-41), anti-CD8-APC-eFluor 780 (Invitrogen, 47-0086-42), anti-CD16-APC-eFluor 780 (Invitrogen, 47-0168-41) and anti-CD14-APC-eFluor 780 (Invitrogen, 47-0149-42) as well as Zombie NIR (BioLegend, 423105) and fluorophore-labelled RBD and ovalbumin (Ova) for 30 min on ice. AccuCheck Counting Beads (Life Technologies, PCBI00) were added to each sample according to the manufacturer’s instructions. Single CD3 CD8 CD14 CD16 CD20 Ova RBD PE RBD AF647 B cells were sorted into individual wells of 96-well plates containing 4 µl of lysis buffer (0.5× PBS, 10 mM dithiothreitol (DTT), 3,000 units per ml of RNasin Ribonuclease Inhibitors (Promega, N2651)) per well using a FACSaria III instrument and FACSDiva software (Becton Dickinson) for acquisition and FlowJo for analysis. The sorted cells were frozen on dry ice and stored at −80 °C or were immediately used for subsequent RNA RT. For B cell phenotype analysis, in addition to the above antibodies, B cells were also stained with the following anti-human antibodies (all at a 1:200 dilution): anti-IgG-BV650 (BD, 740594), anti-ID27-BV786 (BD Biosciences, 563327), anti-CD19-BV605 (BioLegend, 302244), anti-CD71-PerCP-Cy5.5 (BioLegend, 334114), anti-IgG-PECF594 (BD, 562538), anti-IgM-AF700 (BioLegend, 314538) and anti-IgA-Viogreen (Miltenyi Biotec, 130-113-481).

**Antibody sequencing, cloning and expression**

Antibodies were identified and sequenced as described previously. In brief, RNA from single cells was reverse-transcribed (SuperScript III Reverse Transcriptase, Invitrogen, 18080-044), and the DNA was stored at −20 °C or used for subsequent amplification of the variable IGHV, IGL and IGKV genes by nested PCR and Sanger sequencing. Sequence analysis was performed using MacVector. Amplicons from the first PCR were used as templates for sequence- and ligation-independent cloning into antibody expression vectors. Recombinant monoclonal antibodies were produced and purified as previously described.

**Biolayer interferometry**

BLI assays were performed as previously described. In brief, we used the Octet Red instrument (ForteBio) at 30 °C with shaking at 1,000 r.p.m. Epitope binding assays were performed with Protein A biosensor (ForteBio, 18-5010) following the manufacturer’s protocol for a classical sandwich assay as follows:

1. Sensor check: sensors immersed for 30 s in buffer alone (buffer ForteBio 18-1105)
2. Capture first antibody: sensors immersed for 10 min with antibody 1 at 10 µg ml⁻¹
3. Baseline: sensors immersed for 30 s in buffer alone
4. Blocking: sensors immersed for 5 min with IgG isotype control at 10 µg ml⁻¹
5. Baseline: sensors immersed for 30 s in buffer alone
6. Antigen association: sensors immersed for 5 min with RBD at 10 µg ml⁻¹
7. Baseline: sensors immersed for 30 s in buffer alone
8. Association with second antibody: sensors immersed for 5 min with antibody 2 at 10 µg ml⁻¹

Curve fitting was performed using the ForteBio Octet data analysis software (ForteBio).

**Computational analyses of antibody sequences**

Antibody sequences were trimmed on the basis of quality and were annotated using IgBLAST version 1.14 with the IMGT domain delineation system. Annotation was performed systematically using the Change-O toolkit version 0.4.540 (ref. 39). The clonality of the heavy and light chains was determined using DefineClones.py implemented by Change-O version 0.4.5 (ref. 39). The script calculates the Hamming distance between each sequence in the dataset and its nearest neighbour. Distances are subsequently normalized to account for differences in junction sequence length, and clonality is determined on the basis of a cut-off threshold of 0.15. Heavy and light chains derived from the same cell were subsequently paired, and clonotypes were assigned according to their V and J genes using in-house R and Perl scripts. All scripts and the data used to process the antibody sequences are publicly available on GitHub (https://github.com/stratust/igpipeline/tree/igpipeline2_timepoint_v2).

The frequency distributions of human V genes in anti-SARS-CoV-2 antibodies from this study was compared with 131,284,220 heavy and light chain sequences generated by ref. 40 and downloaded from cAb-Rep41, a database of human shared B cell receptor clonotypes available at https://cab-rep.c2b2.columbia.edu/. On the basis of the 150 distinct V genes that made up the 1,650 sequences from the immunoglobulin repertoires of the five participants analysed in this study, we selected the heavy and light chain sequences from the database that were partially encoded by the same V genes and counted them according to the constant region. The frequencies shown in Extended Data Fig. 3 are relative to the source and isotype analysed. We used the two-sided binomial test to check whether the number of sequences belonging to a specific IGHV or IGLV gene in the repertoire was different according to the frequency of the same V gene in the database. The adjusted P values were calculated using false discovery rate correction.

Nucleotide somatic mutations and complementarity-determining region length were determined using in-house R and Perl scripts. For quantification of somatic mutations, IGHV and IGKV nucleotide
sequences were aligned against their closest germline versions using IgBLAST and the number of differences was considered to be nucleotide mutations. The average number of mutations for V genes was calculated by dividing the sum of all nucleotide mutations across all participants by the number of sequences used for the analysis.

Data presentation
The figures were arranged using Adobe Illustrator 2020 and 2022.

Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

Data availability
Data are provided in Supplementary Tables 1–6. The raw sequencing data associated with Fig. 2 have been deposited at GitHub (https://github.com/stratust/igpipeline/tree/igpipeline2_timepoint_v2). This study also used data from A Public Database of Memory and Naive B-Cell Receptor Sequences (https://doi.org/10.5061/dryad.35ks2), PDB (6VYB and 6NB6), cAb-Rep (https://cab-rep.c2b2.columbia.edu/), the Sequence Read Archive (SRP010970) and ref. 40.

Code availability
The computer code used to process the antibody sequences is available at GitHub (https://github.com/stratust/igpipeline/tree/igpipeline2_timepoint_v2).

Author contributions
F.M., Z.W., A.C., T.H., P.D.B. and M.C.N. conceived, designed and analysed the experiments. M.C. and C.G. designed the clinical protocols. F.M., Z.W., A.C., T.B.T., J.D., E.B., M.T., K.G.M., I.S., M.D., C.G. and M.C. recruited participants, executed clinical protocols and processed samples. T.Y.O. and V.R. performed bioinformatic analysis. F.M., Z.W., A.C., T.H., P.D.B. and M.C.N. wrote the manuscript with input from all co-authors.

Acknowledgements
We thank all study participants who devoted time to our research and The Rockefeller University Hospital nursing staff and Clinical Research Support Office. We thank all members of the laboratory of M.C.N. for helpful discussions, Mala Jankovic for laboratory support and K. Gordon for technical assistance with cell sorting experiments. This work was supported by NIH grants P01-AI138398-S1 and 2U19-AI111825 to M.C.N., R37-AI64003 to P.D.B. and R01AI078786 to T.H. F.M. was supported by the Bulgarian Women and Science Fellowship for COVID-19 Research. C.G. was supported by the Robert S. Wennett Post-Doctoral Fellowship, in part by the National Center for Advancing Translational Sciences (National Institutes of Health Clinical and Translational Science Award program, grant UL1-TR001866) and by the Shapiro-Silverberg Fund for the Advancement of Translational Research. P.D.B. and M.C.N. are Howard Hughes Medical Institute (HHMI) Investigators. This article is subject to HHMI’s Open Access to Publications policy. HHMI laboratory heads have previously granted a nonexclusive CC BY 4.0 license to the public and a sublicensable license to HHMI in their research articles. Pursuant to those licenses, the author-accepted manuscript of this article can be made freely available under a CC BY 4.0 license immediately after publication.

Competing interests
The Rockefeller University has filed a provisional patent application in connection with this work, on which M.C.N. is an inventor (US patent 63/021,387). The patent has been licensed by Rockefeller University to Bristol Meyers Squib. P.D.B. has received remuneration from Pfizer for consulting services related to SARS-CoV-2 vaccines.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41586-022-04778-y.

Correspondence and requests for materials should be addressed to Theodora Hatziioannou, Paul D. Bieniasz or Michel C. Nussenzweig.

Peer review information Nature thanks James Crowe and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at http://www.nature.com/reprints.
Extended Data Fig. 1 | Plasma ELISA. Graph shows area under the curve (AUC) for plasma a, IgM and b, IgA antibody binding to Wuhan-Hu-1 SARS-CoV-2 RBD after prime*, 1.3 months (m) and 5 months (m) after the 2nd vaccine dose (Vax2)5,6, and 1 month after the 3rd (Vax3) for n = 42 samples. Lines connect longitudinal samples. Red bars and value represent geometric mean values. Statistical significance was determined by two-tailed Kruskal-Wallis test with subsequent Dunn's multiple comparisons. P-values as indicated.
Extended Data Fig. 2 | Flow Cytometry. a, Gating strategy for phenotyping. Gating was on lymphocytes singlets that were CD19+ or CD20+ and CD3−CD8−CD16−Ova−. Anti-IgG, IgM, IgA, IgD, CD71 and CD27 antibodies were used for B cell phenotype analysis. Antigen-specific cells were detected based on binding to Wuhan-Hu-1 RBD-PE+ and RBD-AF647+. Counting beads were added to each sample and gated based on forward scatter (FSC) and side scatter (SSC) as per manufacturer instructions. b, Representative flow cytometry plots of Wuhan-Hu-1 RBD-specific memory B cells in 8 individuals after prime, 1.3- and 5-months post-Vax2, and 1 month after Vax3. Timepoint of sample collection indicated to the left. Pfizer vaccinees indicated by (P) and Moderna by (M) across the top. c, Graph showing frequency of Wuhan-Hu-1 RBD-specific MBCs expressing activation marker CD71 over time after vaccination for n = 36 samples. Red bar indicated median value. d, Graph showing the phenotype of RBD-specific B cells over time, determined to be either switched MBCs (IgD−CD27+), unswitched MBCs (IgD+CD27+), double negative MBCs (IgD−CD27−) or naïve B cells (IgD+CD27−), for n = 18 samples. Lines connect longitudinal samples. e, Gating strategy for single-cell sorting for CD20+ memory B cells for Wuhan-Hu-1 RBD-PE and Wuhan-Hu-1 RBD-AF647.
Extended Data Fig. 3 | Frequency distribution of human V genes.

**a-c** Comparison of the frequency distribution of human V genes for heavy chain and light chains of anti-RBD Wuhan-Hu-1 antibodies from this study and from a database of shared clonotypes of human B cell receptor generated by Cinque Soto et al. Graph shows relative abundance of human IGHV (a), IGKV (b) and IGLV (c) genes Sequence Read Archive accession SRP010970 (blue), 1.3m-Vax2 antibodies (orange), and 1m-Vax3 antibodies (green).
Extended Data Fig. 4 | Clonality and somatic hypermutation of anti-SARS-CoV-2 Wuhan-Hu-1 RBD antibody clones after third vaccination booster. **a**, Graphs show relative fraction of all clones (persisting and unique), persisting clones only (sequences detected at multiple time points), unique clones only (clonally expanded but detected at a single time point), and singlets (detected only once at a single time point) among all antibody sequences in individuals (n = 5) 5m after the 2nd and 1 month after the 3rd dose. **b**, Number of nucleotide somatic mutations (SHM) in the *IGHV* (left panel) and *IGLV* (right panel) in the antibodies illustrated in Fig. 2c for vaccinees after 1.3- and 5 months post-Vax2 and 1 month after Vax3, compared to the number of mutations obtained after 1.3- or 6.2 months after infection (grey). Statistical significance was determined by Wilcoxon matched-pairs signed rank test (**a**) or by two-tailed Kruskal Wallis test with subsequent Dunn’s multiple comparisons (**b**). P-values as indicated.
Extended Data Fig. 5 | Anti-SARS-CoV-2 RBD monoclonal antibodies. a, Graphs show half-maximal concentration (EC_{50}) of n = 459 monoclonal antibodies measured by ELISA against Wuhan-Hu-1 RBD after prime, 1.3- and 5-months post Vax2, and 1 month after Vax3. b, Graph showing EC_{50} of n = 459 monoclonal antibodies as categorized as either persisting clones detected at multiple time points, unique clones where sequences were clonally expanded but detected at a single time point, or singlets where mAbs were derived from sequences detected once at a single time point. c-d, EC_{50} (c) or IC_{50} neutralizing activity (d) of n = 246 monoclonal antibodies derived from shared clones only. Lines connect the related clones at the indicated time point. Red bars and numbers in a, and b, indicate geometric mean values. Statistical significance was determined by two-tailed Kruskal Wallis test with subsequent Dunn’s multiple comparisons. All experiments were performed at least twice.
Extended Data Fig. 6 | See next page for caption.
Extended Data Fig. 6 | Multiple sequence alignment of RBDs. Sequences used for the alignment are the RBDs of WIV1 (Bat SARS-like coronavirus WIV1, GenBank: KF367457.1), Rp3 (Bat coronavirus Rp3/2004, UniprotKB: Q3I5J5), Rs4081 (Bat SARS-like coronavirus isolate Rs4081, GenBank: KY417143.1), ZC45 (Bat SARS-like coronavirus ZC45, GenBank: AVP78031.1), Rf1 (Bat SARS coronavirus Rf1, GenBank: DQ412042.1), Rs672 (SARS coronavirus Rs_672/2006, GenBank: ACU31032.1), RatG13 (Bat coronavirus RatG13, GenBank: QHR63300.2), SARS-CoV (Severe acute respiratory syndrome coronavirus 2, GenBank: MN985325.1), A022 (SARS coronavirus A022, GenBank: AAV91631.1), Yun11 (Bat coronavirus Cp/Yunnan2011, GenBank: JX993988.1), BM48-31 (Bat coronavirus BM48-31/BGR/2008, NCBI Reference Sequence: NC_014470.1), GZ02 (SARS coronavirus GZ02, GenBank: AAS000031.1), Pangolin (Pangolin coronavirus, GenBank: QIA48632.1), SARS-CoV (Severe acute respiratory syndrome coronavirus, UniProtKB: P59594), ZXC21 (Bat SARS-like coronavirus ZXC21, GenBank: AVP78042.1), SHC014 (Bat SARS-like coronavirus RsSHC014, GenBank: KC881005.1), BtKY72 (Severe acute respiratory syndrome-related coronavirus strain BtKY72, GenBank: KY352407.1), CUHK-W1 (SARS coronavirus CUHK-W1, GenBank: AAP13567.1), and A031 (SARS coronavirus A031, GenBank: AAV97988.1). Multiple sequence alignment of RBDs was processed by Clustal Omega. Sequence conservation was calculated by the ConSurf Database.
Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a  Confirmed

☐  The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement

☐  A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly

☐  The statistical test(s) used AND whether they are one- or two-sided

Only common tests should be described solely by name; describe more complex techniques in the Methods section.

☐  A description of all covariates tested

☐  A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons

☐  A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)

☐  For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted. Give P values as exact values whenever suitable.

☐  For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings

☐  For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes

☐  Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection
- iRIS by MedRIS version 11.02 for clinical data collection and management; BD FACSDiva Software Version 8.0.2 for flow sorting; Glomax Navigator Promega V.3 for neutralization assays; Omega 5.11 by BMG Labtech was used for Elisa Assays.

Data analysis
- Flowio 10.6.2 for FACS analysis; GraphPad Prism 9.3; Microsoft Excel 16.5.7; MacVector 17.5.4 for sequence analysis; Omega MARS V2.10 by BMG Labtech for luminometer; Glomax Navigator V.3 from Promega, ForteBio Octet Data analysis software Version 10.0, Adobe Illustrator 2020 and 2022, BBduk for sequencing read processing, scripts and the data used to process antibody sequences are available on GitHub (https://github.com/stratust/gp_pipeline/tree/gp_pipeline2_timepoint_v2).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Data are provided in Supplementary Tables 1-6. The raw sequencing data associated with Figure 2 have been deposited at Github (https://github.com/stratust/gp_pipeline/tree/gp_pipeline2_timepoint_v2). This study also uses data from "A Public Database of Memory and Naive B-Cell Receptor Sequences" (https://...
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences
- Behavioural & social sciences
- Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

**Sample size**
Sample size of 42 individuals was based on how many study participants could be recruited for serial blood donations at the Rockefeller University Hospital in New York between January 21, 2021, and December 14, 2021. The majority of participants (n=32) were follow-ups from a longitudinal cohort that we previously reported on (Wang et al 2021 and Cho et al 2021), while a smaller subgroup of individuals (n=10) was de novo recruited for this study (for details see Supplementary Table 1).

**Data exclusions**
No data were excluded from the analysis.

**Replication**
All experiments successfully performed at least twice.

**Randomization**
This is not relevant as this is an observational study.

**Blinding**
This is not relevant as this is an observational study.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems | Methods |
|----------------------------------|---------|
| n/a | Involved in the study |
|  | Antibodies |
|  | Eukaryotic cell lines |
|  | Palaeontology and archaeology |
|  | Animals and other organisms |
|  | Human research participants |
|  | Clinical data |
|  | Dual use research of concern |
| n/a | Involved in the study |
|  | ChIP-seq |
|  | Flow cytometry |
|  | MRI-based neuroimaging |

Antibodies

**Antibodies used**

1. Mouse anti-human CD20-PE/Cy7 (BD Biosciences, 335793), clone L27
2. Mouse anti-human CD3-APC-eFluoro 780 (Invitrogen, 47-0037-41), clone OKT3
3. Mouse anti-human CD8-APC-421-eFluoro 780 (Invitrogen, 47-0086-42), clone OKT8
4. Mouse anti-human CD16 APC-eFluoro 780 (Invitrogen, 47-0168-41), clone eBioCB16
5. Mouse anti-human CD14-APC-eFluoro 780 (Invitrogen, 47-0149-4), clone 61D3
6. Zombie NIR (Biolegend, 423105)
7. Mouse anti-IgG BV650 (BD Biosciences, 740594), clone iAg-2
8. Mouse anti-CD27-BV786 (BD Biosciences, 563277), clone L128
9. Mouse anti-human CD19-BV650 (Biolegend, 302244), clone HIB19
10. Mouse anti-human CD71 PerCP/Cy5.5 (Biolegend, 334116), clone CY64
11. Mouse anti-human IgG-PE/Cy594 (BD Biosciences, 562538), clone G18-145
12. Mouse anti-human IgM-AF700 (Biolegend, 314538), clone M3M8-88
13. Mouse anti-human IgA-VioGreen (Miltenyi Biotec, 130-113-481), clone 1511-8E10
14. Peroxidase Goat anti-Human IgG Jackson Immunoresearch 109-036-088
15. Peroxidase Goat anti-Human IgM Jackson Immunoresearch 109-035-129
16. Peroxidase Goat anti-Human IgA Sigma A0295
17. Streptavidin-BV711 (BD biosciences Cat#563262)
18. Streptavidin-PE (BD biosciences Cat#554061)
Eukaryotic cell lines

Policy information about cell lines

Cell line source(s)

293T [ATCC CRL-11268]
293T/ACE2* (Robbiani, D. et al. Nature 584, doi.org/10.1038/s41586-020-2456-9)
HT1080/ACE2 (Schmidt, F. et al. J Exp Med 217, doi:10.1084/jem.20201183)

Authentication

Not authenticated after purchase from ATCC.

Mycoplasma contamination

All cell lines were tested negative for mycoplasma contamination as assessed by Hoechst staining.

Commonly misidentified lines

[See GLQC register]

No commonly misidentified cell lines were used.

Human research participants

Policy information about studies involving human research participants

Population characteristics

Participants were healthy volunteers who had previously received the initial two-dose regimen of either the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) mRNA vaccines against the wildtype (Wuhan-Hu-1) strain of the severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]. Participants were 34 (23-78) years old (median [range]), 22 out of 42 participants were female. 8 participants received the Moderna (mRNA-1273) and 34 received the Pfizer-BioNTech (BNT162b2) vaccine.

Recruitment

Participants were recruited for serial blood donations at the Rockefeller University Hospital in New York between January 21, 2021, and December 14, 2021. The majority of participants (n=32) were follow-ups from a longitudinal cohort that we previously reported on [Wang et al. 2021 and Cho et al., 2021] while a smaller subgroup of individuals (n=10) was de novo recruited for this study [for details see Supplementary Table 1]. Eligible participants (n=42) were healthy adults with no history of infection with SARS-CoV-2 during or prior to the observation period (as determined by clinical history and confirmed through serology testing) who had received two doses of one of the two currently approved SARS-CoV-2 mRNA vaccines, Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2), and this also included a subgroup of individuals (n=33) who had received a third vaccine dose. The specifics of each participant’s vaccination regimen were at the discretion of the individual and their health care provider consistent with current dosing and interval guidelines and, as such, not influenced by our participation in their study. Exclusion criteria included incomplete vaccination status (defined as less than 2 doses), presence of clinical signs and symptoms suggestive of acute infection with or a positive reverse transcription polymerase chain reaction (RT-PCR) results for SARS-CoV-2 in saliva, or a positive (coronavirus disease 2019) COVID-19 serology. No other parameters that could lead to potential self-selection bias were used to exclude or include patients. Participants presented to the Rockefeller University Hospital for blood sample collection and were asked to provide details of their vaccination regimen, possible side effects, comorbidities and possible COVID-19 history.
The study was performed in compliance with all relevant ethical regulations and the protocol (DRO-1006) for studies with human participants was approved by the Institutional Review Board of the Rockefeller University.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

### Flow Cytometry

#### Plots
- The axis labels state the marker and fluorochrome used (e.g., CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a ‘group’ is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

**Sample preparation**

Whole blood samples were obtained from study participants recruited through Rockefeller University Hospital. Peripheral blood mononuclear cells (PBMCs) were separated by Ficoll gradient centrifugation. Prior to sorting, PBMCs were enriched for B cells using a Miltenyi Biotech pan B cell isolation kit (cat. no. 130-101-638) and LS columns (cat. no. 130-042-401).

**Instrument**

FACS Aria III (Becton Dickinson)

**Software**

BD FACSDiva Software Version 8.0.2 and FlowJo 10.6.2

**Cell population abundance**

Sorting efficiency ranged from 40% to 80%. This is calculated based on the number of IgG-specific antibody sequences that could be PCR-amplified successfully from single sorted cells from each donor.

**Gating strategy**

Cells were first gated for lymphocytes in FSC-A (x-axis) versus SSC-A (y-axis). We identify single cells in FSC-A versus FSC-H, and then SSC-A versus SSC-W. We then select for CD20+ Dump: B Cells in dump (anti-CD3-eFluro 780, anti-CD16-eFluro 780, anti-CD8-eFluro 780, anti-CD14-eFluro 780, Zombie NIR) versus CD20 (anti-CD20-PE-Cy7); dump-negative was considered to be signal less than 250, and CD20-positive was taken to be signal greater than 100. We then gate for Ova- B cells in FSC-A versus Ova-8V711; Ova-negative was considered to be all cells with signal less than 100. Select for Sars-CoV-2 RBD double-positive cells in RBD PE versus RBD AlexaFluor 647; this gate was made along the 45° diagonal, above 1000 on both axes.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.